Xeris Biopharma Holdings Goodwill

Xeris Biopharma Holdings (XERS) currently reports a goodwill of $23M as of March 2026. That compares with $23M in the prior-year period — up 0.0% year over year. Use the charts on this page to explore Xeris Biopharma Holdings's goodwill history and peer comparisons.

Xeris Biopharma Holdings's goodwill was unchanged from $23M to $23M — essentially flat versus a year earlier (period ending March 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Xeris Biopharma Holdings reported $23M in goodwill as of March 2026. That compares with $23M in the prior-year period — up 0.0% year over year. Absolute dollar amounts are most useful when compared with prior periods, peers, and related line items such as revenue, assets, or liabilities on Stockcircle.

Start with the current goodwill of $23M, then check the historical chart for trend and the peer comparison chart for relative positioning. From there, open related valuation or income-statement pages for Xeris Biopharma Holdings, and consider following XERS for alerts when major investors trade the stock.

Xeris Biopharma Holdings is classified in the Healthcare sector. On goodwill, it currently shows $23M. Sector peers often share similar capital intensity and growth regimes, so relative rankings inside Healthcare are usually more informative than comparing XERS with unrelated industries.